8 years ago
NeoPhore Raises £3 Million to Develop Cancer Immunotherapy
NeoPhore Ltd., a spin-out from PhoreMost Ltd
based in Cambridge, UK, has secured £3 million in funding from Sixth Element Capital LLP
The investment will be used to advance discoveries made by PhoreMost and its collaborators
NeoPhore aims to develop novel small molecule therapies for cancer treatment by stimulating the immune system, targeting genetic mechanisms that promote neoantigen creation and diversity across numerous cancers.
ProblemHealthcare
"Cancer immunotherapy is not effective for all patients. Some tumors are 'cold' and don't respond to treatments. Existing therapies have limitations in boosting the immune system to fight these cancers."
Solution
"NeoPhore is developing novel small molecule therapies that stimulate the immune system to target 'cold' tumors and improve responses in patients already eligible for cancer immunotherapy. They are using genetic mechanisms to promote the creation of neoantigens, which are unique proteins that can be recognized by the immune system. This approach aims to improve clinical outcomes for cancer patients."
